Literature DB >> 3472638

A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.

J D Borsi, P J Moe.   

Abstract

Concentrations of methotrexate have been determined in the serum and cerebrospinal fluid after 406 infusions of methotrexate to 58 children with acute lymphoblastic leukemia. The dose of methotrexate varied between 500 mg/m2 and 33,600 mg/m2. Pharmacokinetic analysis of the data has been carried out. The effect of dose, age, and number of treatments on steady-state concentration, serum half-life, cerebrospinal fluid (CSF) serum distribution ratio, volume of distribution, systemic clearance of methotrexate was examined. The elevation of dose resulted in a nonproportional increase of the steady-state concentrations both in serum and CSF. The great inpatient and interpatient variations of steady-state concentrations caused only statistically not significant differences in the parameters of different subgroups of dosages. Correlation was found between concentrations of methotrexate in serum and CSF. One to 4 years old children were found to have lower steady-state concentrations of methotrexate in the serum and CSF, greater volume of distribution and faster clearance of the drug. Dose-dependency and age-dependency of methotrexate pharmacokinetics has been concluded.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472638     DOI: 10.1002/1097-0142(19870701)60:1<5::aid-cncr2820600103>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Chemotherapy of childhood lymphoblastic leukaemia: the first 50 years.

Authors:  J Lilleyman
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Authors:  Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

Authors:  C Wolfrom; R Hepp; R Hartmann; H Breithaupt; G Henze
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Authors:  Karen D Wright; John C Panetta; Arzu Onar-Thomas; Wilburn E Reddick; Zoltan Patay; Ibrahim Qaddoumi; Alberto Broniscer; Giles Robinson; Frederick A Boop; Paul Klimo; Deborah Ward; Amar Gajjar; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2014-10-24       Impact factor: 3.333

Review 5.  Updates on Primary Central Nervous System Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

6.  7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.

Authors:  J D Borsi; E Sagen; I Romslo; L Slørdal; P J Moe
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Naomi J Winick; Pierre Wacker; Xiaomin Lu; Meenakshi Devidas; Jonathan J Shuster; Donald H Mahoney; Stephen J Lauer; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2012-01       Impact factor: 1.289

8.  Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.

Authors:  M D de Smet; V S Vancs; D Kohler; D Solomon; C C Chan
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

9.  Chemotherapy in newly diagnosed primary central nervous system lymphoma.

Authors:  Nooshin Hashemi-Sadraei; David M Peereboom
Journal:  Ther Adv Med Oncol       Date:  2010-07       Impact factor: 8.168

Review 10.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.